As of August 2025, nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64
Claims generally cover the following: Medical expenses , past and future, including hospitalization, surgery, and ongoing treatment Lost wages and lost earning capacity Pain and suffering Loss of consortium for spouses and family members Wrongful death damages , in cases where GLP-1-related complications contributed to a loved one's death Every case is different, and past results do not guarantee future outcomes
180,181 Several lines of evidence suggest that circulating adiponectin is closely related to ceramide concentrations, wherein adiponectin increases ceramidase activity associated with its two receptors AdipoR1/AdipoR2, while lower concentrations of circulating adiponectin increases ceramide concentrations in different tissues
Prescription Medications to Treat Overweight & Obesity
Studies show GIP receptor activation on fat tissue promotes improved lipid handling, enhanced insulin sensitivity in fat cells specifically, and changes in fat distribution patterns
The subcutaneous injection can be administered at any time of day, with or without food, providing additional flexibility